Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206103 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2NPSR1LOXL2IDO1F7 | |
| SCHEMBL9417648 | 0.75 | PTPN11 (0.42) | SMN1; SMN2DYRK1ANPC1RAB9AGAA | |
| SCHEMBL3125096 | 0.75 | CA2 (0.39) | NPSR1DYRK1ANPC1RAB9AGAA | |
| SCHEMBL207089 | 0.75 | GFER (0.36) | SMN1; SMN2DYRK1ANPC1RAB9AKDM4E | |
| SCHEMBL207013 | 0.75 | DYRK1A (0.36) | SMN1; SMN2DYRK1ANPC1RAB9APPARA | |
| SCHEMBL1832902 | 0.75 | MAPT (0.38) | SMN1; SMN2DYRK1ANPC1RAB9ACYP2A6 | |
| SCHEMBL20542591 | 0.74 | — | — | |
| SCHEMBL211098 | 0.74 | MAPK13 (0.36) | DYRK1A | |
| SCHEMBL5541045 | 0.72 | PIK3CA (0.42) | GAAPIK3CGALDH1A1 | |
| SCHEMBL6364831 | 0.72 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248965-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| EP-3676297-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| US-20200331900-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2020-10-22 | — | — | US | claimed |
| EP-3676297-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-07-08 | — | — | EP | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111201245-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-26 | — | — | CN | claimed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019046779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-03-07 | — | — | WO | claimed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030176361-A1 | Furanone derivatives | MONSANTO TECHNOLOGY LLC | 2003-09-18 | — | — | US | claimed |
| WO-2003064403-A1 | FURANONE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-5624937-A | TREATMENT OF ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | claimed |
| US-5401763-A | Derivatives of arylacetic esters displaying high fungicidal activity | Ministero Dell `Universita` e Della Ricerca Scientifica e Technologica (IT) | 1995-03-28 | — | — | US | claimed |
| EP-0611760-A1 | Derivatives of arylacetic esters displaying high fungicidal activity | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1994-08-24 | — | — | EP | claimed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | claimed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | claimed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331900-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | SMN1; SMN2 1178/4885NPSR1 3538/4885LOXL2 4609/4885 |
| US-20030176361-A1 | Furanone derivatives | HSPA9, HSF1, IL1B | SMN1; SMN2 107/4885NPSR1 1907/4885LOXL2 2048/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | SMN1; SMN2 3963/4885NPSR1 473/4885LOXL2 104/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | SMN1; SMN2 1096/4885NPSR1 3465/4885LOXL2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.